Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

GALACTIC-HF

- PMLiVE

Amgen’s Xgeva cleared in US for rare bone cancer complication

Hypercalcaemia of malignancy affects around 2.7% of cancer patients

- PMLiVE

New ASPIRE data boosts Amgen’s Kyprolis

Trial results presented at ASH show drug can be safely added to standard chemotherapy

- PMLiVE

Early approval for Amgen’s breakthrough leukaemia drug

32% of patients in remission after at least four weeks of Blincyto infusion

- PMLiVE

Novartis’ heart failure drug on EMA’s fast track

Candidate is the first cardiovascular drug to get accelerated review in the EU

- PMLiVE

Amgen/AZ confirm brodalumab psoriasis filing in 2015

Drug demonstrates greater effectiveness than J&J’s Stelara

- PMLiVE

Deaths cause Amgen to drop stomach cancer drug

Increase in patient mortality in patients taking rilotumumab during trial

- PMLiVE

Servier licenses device that could ‘reshape’ diabetes care

Tiny pump implant to deliver GLP-1 agonist

- PMLiVE

Amgen and AZ’s psoriasis antibody beats Stelara in study

Brodalumab cleared all skin lesions in 37% compared to Stelara’s 18.5%

- PMLiVE

FDA to review Amgen’s cholesterol drug

US regulator accepts first in new class of PCSK9 inhibitors

- PMLiVE

Amgen’s trebananib misses survival target in ovarian cancer

First phase III trial improved survival rates by just one month

- PMLiVE

Amgen should split up, says investor

Hedge fund manager Daniel Loeb criticises big biotech firm's 'bloated cost structure'

- PMLiVE

Amgen should split up, says investor

Hedge fund manager Daniel Loeb criticises big biotech firm's 'bloated cost structure'

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links